Aravive Inc. (ARAV) PT Raised to $31 at H.C. Wainwright
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/24/2024
- Wall Street closes higher as investors digest earnings, megacap outlook
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil rises as dollar slips, focus shifts to economic data
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Wolfe Research Downgrades Warner Brothers Discovery (WBD) to Underperform, 'out of concern that an incipient advertising downturn put guidance at risk'
- Forward Air (FWRD) Appoints Shawn Stewart as CEO
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
Aravive Inc. (ARAV) PT Raised to $28 at Wedbush
November 20, 2019 12:12 PM ESTWedbush analyst David Nierengarten raised the price target on Aravive Inc. (NASDAQ: ARAV) to $28.00 (from $12.00) while maintaining a Outperform rating.
... MoreAravive Inc. (ARAV) PT Raised to 'Street High' $36 at Piper Jaffray
November 20, 2019 10:34 AM ESTPiper Jaffray analyst Edward Tenthoff raised the price target on Aravive Inc. (NASDAQ: ARAV) to $36.00 (from $15.00) while maintaining a Overweight rating.
... MoreAravive Inc. (ARAV) Halted on LUDP
November 20, 2019 9:46 AM ESTAravive Inc. (NASDAQ: ARAV) Halted on LUDP
... MorePre-Open 11/20: (ARAV) (I) (TGT) Higher (PDD) (URBN) (MUX) Lower (more...)
November 20, 2019 9:16 AM ESTToday's Pre-Open Movers
Aravive, Inc. (Nasdaq: ARAV) 214.9% HIGHER; announced new positive data from the ongoing Phase 1b portion of the Phase 1b/2 clinical trial of AVB-500 in platinum-resistant recurrent ovarian cancer patients. The data from the first 31 patients treated at the 10mg/kg dose are maturing and affirm earlier findings on the relationship between AVB-500 levels and anti-tumor response. In this data analysis, high serum drug levels of AVB-500 were strongly predictive of anti-tumor activity with statistically significant correlation to progression-free survival (PFS; p=0.0066). PFS is the primary endpoint for... More
Aravive Inc. (ARAV) Extends Gain, Up 250%
November 20, 2019 7:43 AM ESTAravive Inc. (NASDAQ: ARAV) Extends Gain, Up 250%
Aravive Inc. (ARAV) Climbs 80% After Positive Data from Ongoing Trial of AVB-500 in Ovarian Cancer
November 20, 2019 7:21 AM ESTAravive Inc. (NASDAQ: ARAV) Climbs 80% After Positive Data from Ongoing Trial of AVB-500 in Ovarian Cancer
... MoreAravive (ARAV) Reports Positive Data Supporting Relationship Between AVB-500 Levels, Anti-Tumor Activity and Progression Free Survival in Women with Ovarian Cancer
November 20, 2019 7:02 AM ESTAravive, Inc. (Nasdaq: ARAV) today announced new positive data from the ongoing Phase 1b portion of the Phase 1b/2 clinical trial of AVB-500 in platinum-resistant recurrent ovarian cancer patients. The data from the first 31 patients treated at the 10mg/kg dose are maturing and affirm earlier findings on the relationship between AVB-500 levels and anti-tumor response. In this data analysis, high serum drug levels of AVB-500 were strongly predictive of anti-tumor activity with statistically significant correlation to progression-free survival (PFS; p=0.0066). PFS is the primary endpoint for platinum-resistant ovarian cancer clinical... More
